Description

Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury[1][2][3].—COVID-19-immunoregulation–C45H66N18O7S—-[1]Madhav Bhatia, et al. Treatment with antileukinate, a CXCR2 chemokine receptor antagonist, protects mice against acute pancreatitis and associated lung injury. Regul Pept. 2007 Jan 10;138(1):40-8.|[2]Yuji Fukuno, et al. Chemokine receptor inhibitor, Antileukinate, suppressed ovalbumin-induced eosinophilic inflammation in the airway. Cytokine. 2003 Jun 7;22(5):116-25.|[3]S HayashiY, et al. Antileukinate, a hexapeptide inhibitor of CXC-chemokine receptor, suppresses bleomycin-induced acute lung injury in mice. Lung. 2002;180(6):339-48.–138559-60-1–1003.19—-CC(N[C@@H](CCCNC(N)=N)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CS)C(N[C@H](C(N)=O)CCCNC(N)=N)=O)=O)CC1=CNC2=C1C=CC=C2)=O)CC3=CNC4=C3C=CC=C4)=O)CCCNC(N)=N)=O)=O–Inflammation/Immunology–10 mM in DMSO–CXCR—-GPCR/G Protein;Immunology/Inflammation–Peptides